CA2692823A1 - Anticorps modifiant une maladie cancereuse - Google Patents

Anticorps modifiant une maladie cancereuse Download PDF

Info

Publication number
CA2692823A1
CA2692823A1 CA 2692823 CA2692823A CA2692823A1 CA 2692823 A1 CA2692823 A1 CA 2692823A1 CA 2692823 CA2692823 CA 2692823 CA 2692823 A CA2692823 A CA 2692823A CA 2692823 A1 CA2692823 A1 CA 2692823A1
Authority
CA
Canada
Prior art keywords
monoclonal antibody
antibody
isolated monoclonal
cdmab
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA 2692823
Other languages
English (en)
Inventor
Helen P. Findlay
Susan E. Hahn
David S. F. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692823A1 publication Critical patent/CA2692823A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2692823 2007-07-16 2008-07-14 Anticorps modifiant une maladie cancereuse Withdrawn CA2692823A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94994207P 2007-07-16 2007-07-16
US60/949,942 2007-07-16
PCT/CA2008/001289 WO2009009882A1 (fr) 2007-07-16 2008-07-14 Anticorps modifiant une maladie cancéreuse

Publications (1)

Publication Number Publication Date
CA2692823A1 true CA2692823A1 (fr) 2009-01-22

Family

ID=40259250

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692823 Withdrawn CA2692823A1 (fr) 2007-07-16 2008-07-14 Anticorps modifiant une maladie cancereuse

Country Status (9)

Country Link
US (1) US20090022661A1 (fr)
EP (1) EP2178919A1 (fr)
KR (1) KR20100028642A (fr)
CN (1) CN101743255A (fr)
AU (1) AU2008278228A1 (fr)
BR (1) BRPI0814111A2 (fr)
CA (1) CA2692823A1 (fr)
TW (1) TW200920400A (fr)
WO (1) WO2009009882A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191120A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191119A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
CN102939934B (zh) * 2012-11-08 2017-01-18 同济大学 整体可视化人肺腺癌h1650裸鼠模型及其建立与应用
EP3029175A1 (fr) 2014-12-05 2016-06-08 Basf Se Procédé pour la production de films minces poreux
WO2017093265A1 (fr) 2015-11-30 2017-06-08 Basf Se Procédé pour la production de films métalliques
WO2017093283A1 (fr) 2015-12-02 2017-06-08 Basf Se Procédé permettant la production de minces films inorganiques
EP3408273B1 (fr) 2016-01-27 2020-06-17 Basf Se Procédé pour la production de films minces inorganiques
CN109072431A (zh) 2016-04-15 2018-12-21 巴斯夫欧洲公司 产生无机薄膜的方法
SG11201810120VA (en) 2016-07-18 2019-02-27 Basf Se Hapto-3-pentadienyl cobalt or nickel precursors and their use in thin film deposition processes
KR102467795B1 (ko) 2016-08-31 2022-11-18 바스프 에스이 얇은 무기 필름의 생성 방법
CN109844172A (zh) 2016-10-13 2019-06-04 巴斯夫欧洲公司 生产含金属膜的方法
CN109890997A (zh) 2016-10-25 2019-06-14 巴斯夫欧洲公司 产生薄含硅膜的方法
WO2018108628A1 (fr) 2016-12-13 2018-06-21 Basf Se Procédé de génération de couches minces contenant du silicium
JP2021507123A (ja) 2017-12-20 2021-02-22 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 金属含有膜の生成方法
CN111954674B (zh) 2018-04-17 2023-09-29 巴斯夫欧洲公司 铝前体和生成含金属膜的方法
WO2019206746A1 (fr) 2018-04-23 2019-10-31 Basf Se Procédé de génération de films contenant du métal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002226211A1 (en) * 2001-12-21 2003-07-15 Arius Research, Inc. Individualized anti-cancer antibodies
US20080213170A1 (en) * 2007-01-23 2008-09-04 Young David S F Cancerous Disease Modifying Antibodies
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
KR20100028642A (ko) 2010-03-12
AU2008278228A1 (en) 2009-01-22
EP2178919A1 (fr) 2010-04-28
TW200920400A (en) 2009-05-16
WO2009009882A1 (fr) 2009-01-22
US20090022661A1 (en) 2009-01-22
CN101743255A (zh) 2010-06-16
BRPI0814111A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
US20090022661A1 (en) Cancerous disease modifying antibodies
US20090022662A1 (en) Cancerous disease modifying antibodies
US20090022660A1 (en) Cancerous disease modifying antibodies
US8129502B2 (en) Cancerous disease modifying antibodies
US20090191119A1 (en) Cancerous disease modifying antibodies
US20090068099A1 (en) Cancerous disease modifying antibodies
US20100015045A1 (en) Cancerous Disease Modifying Antibodies
US20080241137A1 (en) Cancerous disease modifying antibodies
US20090068100A1 (en) Cancerous disease modifying antibodies
US20080279767A1 (en) Cancerous disease modifying antibodies
US20080131365A1 (en) Cancerous disease modifying antibodies
US20090191197A1 (en) Cancerous disease modifying antibodies
US20090191120A1 (en) Cancerous disease modifying antibodies
US20090304579A1 (en) Cancerous Disease Modifying Antibodies
US20090304578A1 (en) Cancerous Disease Modifying Antibodies
US20090285751A1 (en) Cancerous disease modifying antibodies
WO2011004899A1 (fr) Anticorps de modification d’une maladie cancéreuse

Legal Events

Date Code Title Description
AZWI Withdrawn application